Top-line data for Sanofi SA and Regeneron Pharmaceuticals Inc.'s phase II trial of the IL-33 antibody REGN-3500 show patients with moderate to severe asthma treated with Dupixent (dupilumab) monotherapy did numerically better than REGN-3500 across all endpoints. And combining REGN-3500 and Dupixent did not demonstrate increased benefit compared to Dupixent monotherapy.

Seven and Eight Biopharmaceuticals Inc. has signed a clinical research collaboration agreement with Roche Holding AG to explore the combination of BDB-001, an immune modulator targeting Toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against checkpoint target PD-L1, in treating solid tumors.

Denovo Biopharma LLC has licensed ORM-12741 from Orion Corp., along with global rights to develop, manufacture and commercialize the alpha-2c adrenoceptor antagonist that has failed several previous clinical trials.

Less than a month after changing its name from Flx Bio Inc., the newly minted Rapt Therapeutics Inc. has extended its series C financing by securing an additional $37 million.

While VBI Vaccines Inc.'s Protect phase III top-line data showed the hepatitis B drug Sci-B-Vac met its co-primary endpoints, failure to meet a secondary endpoint sunk the company stock by 65.6% on Monday.

Savara Inc.'s stock (NASDAQ:SVRA) plummeted 75.2% Thursday as top-line data from Impala, the phase III trial of Molgradex, showed the study failed to meet its primary endpoint in rare lung disease autoimmune pulmonary alveolar proteinosis.

Swedish Orphan Biovitrum AB (Sobi) shed some old skin to grow some new by expanding its Novimmune SA deal by acquiring emapalumab (NI-0501, branded as Gamifant) and all its related assets. Sobi also gets all emapalumab employees involved in the drug's clinical and biopharmaceutical development.

Deciphera Pharmaceuticals Inc. and Zai Lab Ltd. agreed to develop and commercialize ripretinib in mainland China, Hong Kong, Macau and Taiwan for patients with gastrointestinal stromal tumors (GIST).

Artizan Biosciences Inc. has kept a low profile since its creation in 2016, quietly raising money and forging a path to finding a cure for certain diseases involving human intestinal microbiota. It stepped out Monday when it announced completion of a series A funding round totaling $12 million.

Vertex Pharmaceuticals Inc. plans to up its gene editing game by expanding an existing collaboration with Crispr Therapeutics AG and acquiring privately held Exonics Therapeutics Inc. to develop therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).